The effect of heparin after primary percutaneous coronary intervention on short-term clinical outcomes in patients with ST-segment elevation myocardial infarction

Mohammed Rouzbahani, Mohsen Rezaie, Nahid Salehi, Parisa Janjani, Reza Heidari Moghadam, Alireza Rai, Nafiseh Montazeri, Arsalan Naderipour, Etrat Javadi Rad, Nader Asgari, Sousan Mahmoudi, Sayeh Motevaseli, Javad Azimivaghar


Background: Doing percutaneous coronary intervention (PCI) in the first hours of myocardial infraction (MI) is effective in re-establishment of blood flow. Anticoagulation treatment should be prescribed in patients undergoing PCI to decrease the side effects of ischemia. The aim of this study is to determine the effect of heparin prescription after PCI on short-term clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). 

Materials: This randomized clinical trial study was conducted at Imam Ali cardiovascular center at Kermanshah university of medical science (KUMS), Iran. Between April 2019 to October 2019, 400 patients with STEMI which candidate to PCI were enrolled. Patients randomly divided in two groups: intervention group (received 5,000 units of heparin after PCI until first 24 hours, every 6 hours) and control group (did not receive heparin). Data were collected using a checklist developed based on the study's aims. Differences between groups were assessed using independent t-tests and chi-square (or Fisher exact tests).

Result: Observed that, mean prothrombin time (PT) (13.30±1.60 vs. 12.21±1.15, p<0.001) and partial thromboplastin time (PTT) (35.30±3.08 vs. 34.41±3.01, p=0.003) were significantly higher in intervention group compared to control group. Thrombolysis in myocardial infarction (TIMI) flow grade 0/1 after primary PCI was significantly more frequently in control group (5.5% vs. 1.0%, p=0.034). The mean of ejection fraction (EF) after PCI (47.58±7.12 vs. 45.15±6.98, p<0.001) was significantly higher in intervention group. Intervention group had a statistically significant shorter length of hospital stay (4.71±1.03 vs. 6.12±1.10, p<0.001). There was higher incidence of re-vascularization (0% vs. 3.0%; p=0.013) and re-MI (0% vs. 2.5%; p=0.024) in the control group.

Conclusion: Performing primary PCI with receiving heparin led to improve TIMI flow and consequently better EF. Receiving heparin is associated with lower risk of re-MI and re-vascularization.


MI, PCI, Outcome, Iran, Heparin

Full Text:



Pieris RR, Al-Sabti HA, Al-Abri QSA, Rizvi SGA. Prevalence pattern of risk factors for coronary artery disease among patients presenting for coronary artery bypass grafting in Oman. Oman medi J. 2014;29:203.

Shyu K-G, Wu C-J, Mar G-Y, Hou CJ-Y, Li A-H, Wen M-S et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndromed observations from the Taiwan ACS full spectrum registry. Acta Cardiol Sin. 2011;27:e44.

Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann translational med. 2016;4(10)194.

Beig JR, Tramboo NA, Kumar K, Yaqoob I, Hafeez I, Rather FA, et al. Components and determinants of therapeutic delay in patients with acute ST-elevation myocardial infarction: A tertiary care hospital-based study. J Saudi Heart Asso. 2017;29:7-14.

Windecker S, Hernández-Antolín R-A, Stefanini GG, Wijns W, Zamorano JL. Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Eu Society Cardiol. 2014;10:T23-31.

O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am college cardiol. 2013;61:e78-e140.

Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch med sci. 2016;12:1181.

Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L et al. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC. Cardiovasc Interv. 2015;8:414-23.

Zamani B, Abdollahi A, Mardi A. The effect of heparin prescription before primary PCI on long-term and short-term clinical and para clinical results and the mortality of patients with acute coronary syndrome. Int J Basic Clin Pharmacol. 2018;7:748-52.

Zijlstra F, Ernst N, de Boer M-J, Nibbering E, Suryapranata H, Hoorntje JC et al. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am College of Cardiol. 2002;39:1733-7.

Verheugt FW, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JG. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am College Cardiol. 1998;31:289-93.

Chung W-Y, Han M-J, Cho Y-S, Kim K-I, Chang H-J, Youn T-J et al. Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. Circulation J. 2007;7(1):862-7.

Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H, de Boer M-J et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am College Cardiol. 2000;35:600-4.

Labèque JN, Jaïs C, Dubos O, Denard M, Berhouet M, Leroux L et al. Prehospital administration of enoxaparin before primary angioplasty for ST‐elevation acute myocardial infarction. Catheter cardiovas interven. 2006;67:207-13.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D et al. Bivalirudin during primary PCI in acute myocardial infarction. N Eng J Med. 2008;358:2218-30.

Bonello L, De Labriolle A, Roy P, Steinberg DH, Slottow TLP, Xue Z et al. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revascul Med. 2009;10:156-61.

Steg PG, Van't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369:2207-17.

Jovin IS, Shah RM, Patel DB, Rao SV, Baklanov DV, Moussa I et al. Outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction via radial access anticoagulated with bivalirudin versus heparin: a report from the National Cardiovascular Data Registry. JACC: Cardiovasc Interv. 2017;10:1102-11.